Top Analyst Reports for Novartis, American Express & ConocoPhillips
https://www.zacks.com/commentary/2259373/top-analyst-reports-for-novartis-american-express-conocophillips?cid=CS-ZC-FT-research_daily-2259373
Apr 22, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
0
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/04/17/2-high-yield-dividend-stocks-to-hold-for-10-years/?source=iedfolrf0000001
Apr 17, 2024 - These income stocks look like good options at current levels.
0
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
https://www.fool.com/investing/2024/04/14/looking-for-an-easy-way-to-earn-passive-income-thi/?source=iedfolrf0000001
Apr 14, 2024 - Think globally with this high-yielding ETF.
0
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
https://www.zacks.com/stock/news/2254812/novartis-nvs-inks-deal-for-arvn-s-prostate-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254812
Apr 12, 2024 - Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
0
Novartis (NVS) to Undertake Job Cuts in Development Department
https://www.zacks.com/stock/news/2253912/novartis-nvs-to-undertake-job-cuts-in-development-department?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253912
Apr 11, 2024 - Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
0
Novartis (NVS) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2249443/novartis-nvs-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2249443
Apr 02, 2024 - In the most recent trading session, Novartis (NVS) closed at $94.41, indicating a -1.52% shift from the previous trading day.
0
Novartis (NVS) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2245727/novartis-nvs-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2245727
Mar 25, 2024 - In the most recent trading session, Novartis (NVS) closed at $95.73, indicating a -0.52% shift from the previous trading day.
0
Novartis (NVS) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2242497/novartis-nvs-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2242497
Mar 18, 2024 - In the latest trading session, Novartis (NVS) closed at $95.92, marking a -1.39% move from the previous day.
0
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089
Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
0
AGFA Gevaert NV (AFGVF) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4678085-agfa-gevaert-nv-afgvf-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 13, 2024 - AGFA Gevaert NV (OTCPK:AFGVF) Q4 2023 Earnings Conference Call March 13, 2024 6:00 AM ETCompany ParticipantsPascal Juery - President, CEO, President,...
0
Page 1>